Summary & Overview
HCPCS Level II L8605: Anal Canal Injectable Bulking Agent
HCPCS Level II code L8605 identifies a 1 ml injectable bulking agent composed of dextranomer/hyaluronic acid copolymer, billed inclusive of shipping and necessary supplies, for use in the anal canal. Nationally, this code matters because it captures the supply component of minimally invasive anorectal procedures that address fecal incontinence and related conditions, informing payer coverage, product utilization, and supply-chain reimbursement for clinicians and facilities. Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn the clinical context of the product, the typical settings where the implant is supplied and administered, and the types of benchmarks and policy considerations that commonly accompany HCPCS Level II supply codes. The publication summarizes billing considerations for the supply itself, how payers commonly treat injectable implant supplies, and notes where input is not available. It also outlines where to look for updates on coverage policies and reimbursement rules that affect supply billing and facility administration. Data not available in the input includes payer-specific allowable amounts, claim frequency, and associated ICD-10 diagnosis codes.
Billing Code Overview
HCPCS Level II code L8605 describes an injectable bulking agent, specifically a dextranomer/hyaluronic acid copolymer implant, supplied in 1 ml vials and billed as including shipping and necessary supplies. This product is used as an anal canal injectable bulking agent intended for procedures addressing anorectal or continence-related disorders.
-
Service type: Injectable implant/bulking agent administration
-
Typical site of service: Ambulatory surgical center, outpatient procedural suite, or clinician office setting where minor anorectal procedures are performed
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to a colorectal or gastroenterology clinic with symptomatic fecal urgency, fecal incontinence, or internal anal sphincter dysfunction after conservative measures (dietary modification, pelvic floor therapy, medications) have failed. The patient has undergone clinical evaluation including focused anorectal history, physical examination with inspection and digital rectal exam, and anorectal manometry or endoanal ultrasound as indicated. After shared decision-making, the clinician schedules an in-office or ambulatory procedure to inject an anal canal bulking agent (L8605) to augment the anorectal mucosa and improve coaptation of the anal canal.
The procedure is typically performed in an outpatient clinic procedure room or ambulatory surgical center under local anesthesia with or without minimal sedation. The clinician assembles the 1 ml dextranomer/hyaluronic acid copolymer implant kit, prepares the perianal skin with antiseptic, identifies target injection sites circumferentially or at specific clock positions, and injects small aliquots into the submucosal plane of the anal canal. Post-procedure monitoring is brief; patients receive discharge instructions on wound care, activity limitations, and signs of complications. Follow-up visits assess symptom response and consider repeat injection if partial response is observed.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 |